West Pharma (WST) Reports In-Line Q3 EPS; Narrows EPS Outlook
Get Alerts WST Hot Sheet
Price: $385.73 --0%
EPS Growth %: -21.2%
Financial Fact:
Dividends declared per share: 0.13
Today's EPS Names:
DGICA, UXIN, TOWN, More
EPS Growth %: -21.2%
Financial Fact:
Dividends declared per share: 0.13
Today's EPS Names:
DGICA, UXIN, TOWN, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q3 EPS of $0.53, in-line with the analyst estimate of $0.53. Revenue for the quarter came in at $376.7 million versus the consensus estimate of $371.25 million.
GUIDANCE:
West Pharma sees FY2016 EPS of $2.17-$2.22, versus prior guidance of $2.15-$2.25 and the consensus of $2.21. West Pharma sees FY2016 revenue of $1.51-1.52 billion, versus the consensus of $1.51 billion.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) stock slips despite earnings beat
- IMAX Corp. (IMAX) Tops Q1 EPS by 7c
- S&P Global (SPGI) Tops Q1 EPS by 36c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!